Impax Asset Management Group plc Takes Position in Insulet Corporation $PODD

Impax Asset Management Group plc bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 9,667 shares of the medical instruments supplier’s stock, valued at approximately $2,984,000.

Other institutional investors also recently bought and sold shares of the company. Krilogy Financial LLC bought a new position in Insulet during the third quarter valued at $330,000. Baader Bank Aktiengesellschaft grew its holdings in Insulet by 7.0% during the 3rd quarter. Baader Bank Aktiengesellschaft now owns 1,643 shares of the medical instruments supplier’s stock valued at $505,000 after purchasing an additional 107 shares during the last quarter. Wealthfront Advisers LLC lifted its stake in Insulet by 1.5% in the third quarter. Wealthfront Advisers LLC now owns 7,878 shares of the medical instruments supplier’s stock worth $2,432,000 after purchasing an additional 116 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Insulet by 0.9% during the third quarter. Oppenheimer Asset Management Inc. now owns 20,730 shares of the medical instruments supplier’s stock valued at $6,400,000 after buying an additional 193 shares during the period. Finally, Azzad Asset Management Inc. ADV grew its stake in shares of Insulet by 31.4% during the third quarter. Azzad Asset Management Inc. ADV now owns 14,716 shares of the medical instruments supplier’s stock valued at $4,543,000 after buying an additional 3,519 shares during the last quarter.

Analyst Ratings Changes

Several brokerages have commented on PODD. Stifel Nicolaus cut their price objective on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Leerink Partners upped their price target on shares of Insulet from $385.00 to $386.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Zacks Research downgraded shares of Insulet from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 5th. Jefferies Financial Group boosted their price objective on shares of Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Finally, Raymond James Financial raised their target price on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. Twenty analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $374.10.

Insulet Stock Down 0.6%

NASDAQ:PODD opened at $250.85 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 2.87 and a quick ratio of 2.18. Insulet Corporation has a 1-year low of $230.05 and a 1-year high of $354.88. The company has a 50-day moving average of $279.92 and a 200 day moving average of $307.07. The firm has a market cap of $17.65 billion, a PE ratio of 72.71, a price-to-earnings-growth ratio of 1.43 and a beta of 1.41.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.